EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Toxic epidermal necrolysis after the administration of enfortumab vedotin for urinary bladder urothelial carcinoma

Yuji Mimura, Aya Kobayashi, Haruhiko Utazu, Yuki Matsumoto, Hiroya Mizusawa iD

IJU Case Reports · 2023-03 · 6 (2) · 111-115

DOI: 10.1002/iju5.12562 ↗

Kurz gefasst

Fallbericht in der Zeitschrift IJU Case Reports, online erschienen am 02.12.2022. Verfasst von Yuji Mimura und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, NHO Shinshu Ueda Medical Center Ueda Nagano Japan. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Enfortumab vedotin is a novel drug for locally advanced or metastatic urothelial carcinoma, but it is associated with a high incidence of skin reactions (up to 47.0%). Case presentation A 71‐year‐old male was administered enfortumab vedotin for bladder cancer associated with lymph node metastases. Slight erythema of the upper limbs appeared on Day 5. Erythema gradually worsened. On Day 8, second administration was performed. On Day 12, based on the extents of blisters, erosion, and epidermolysis, a diagnosis of toxic epidermal necrolysis was made. The patient died of multiple organ failure on Day 18.

Conclusion

As serious cutaneous toxicity may appear early after the start of administration, it is important to consider the timing of the second administration of the initial course carefully. In cases of skin reaction, reduction or discontinuation should be considered.

Schlagwörter

Stichwörter der Autor:innen

Stevens–Johnson syndromeadverse eventantibody‐drug conjugatecutaneous toxicitymetastatic bladder cancer

Autor:innen und Institutionen

  • Department of Urology, NHO Shinshu Ueda Medical Center Ueda Nagano Japan.
  • Department of Dermatology Shinshu Ueda Medical Center Ueda Nagano Japan.

ORCID-Profile: Hiroya Mizusawa

Zitieren

APA

Mimura, Y., Kobayashi, A., Utazu, H., Matsumoto, Y., & Mizusawa, H. (2023). Toxic epidermal necrolysis after the administration of enfortumab vedotin for urinary bladder urothelial carcinoma. IJU Case Reports, 6(2), 111-115. https://doi.org/10.1002/iju5.12562

Vancouver

Mimura Y, Kobayashi A, Utazu H, Matsumoto Y, Mizusawa H. Toxic epidermal necrolysis after the administration of enfortumab vedotin for urinary bladder urothelial carcinoma. IJU Case Reports. 2023;6(2):111-115. doi:10.1002/iju5.12562

BibTeX
@article{Mimura2023,
  author = {Mimura, Yuji and Kobayashi, Aya and Utazu, Haruhiko and Matsumoto, Yuki and Mizusawa, Hiroya},
  title = {Toxic epidermal necrolysis after the administration of enfortumab vedotin for urinary bladder urothelial carcinoma},
  journal = {IJU Case Reports},
  year = {2023},
  volume = {6},
  number = {2},
  pages = {111--115},
  doi = {10.1002/iju5.12562}
}
Kostenlos starten →